- Home
- GANX vs ANTX Comparison
GANX vs ANTX Comparison
Compare GANX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- ANTX
- Stock Information
- Founded
- GANX 2017
- ANTX 2017
- Country
- GANX United States
- ANTX United States
- Employees
- GANX N/A
- ANTX N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- ANTX Health Care
- Exchange
- GANX Nasdaq
- ANTX Nasdaq
- Market Cap
- GANX 41.9M
- ANTX 37.6M
- IPO Year
- GANX 2021
- ANTX 2022
- Fundamental
- Price
- GANX $2.28
- ANTX $1.27
- Analyst Decision
- GANX Strong Buy
- ANTX Hold
- Analyst Count
- GANX 5
- ANTX 5
- Target Price
- GANX $7.60
- ANTX $3.50
- AVG Volume (30 Days)
- GANX 264.8K
- ANTX 143.7K
- Earning Date
- GANX 11-14-2024
- ANTX 11-13-2024
- Dividend Yield
- GANX N/A
- ANTX N/A
- EPS Growth
- GANX N/A
- ANTX N/A
- EPS
- GANX N/A
- ANTX N/A
- Revenue
- GANX N/A
- ANTX N/A
- Revenue This Year
- GANX N/A
- ANTX N/A
- Revenue Next Year
- GANX N/A
- ANTX N/A
- P/E Ratio
- GANX N/A
- ANTX N/A
- Revenue Growth
- GANX N/A
- ANTX N/A
- 52 Week Low
- GANX $0.89
- ANTX $0.87
- 52 Week High
- GANX $5.33
- ANTX $21.40
- Technical
- Relative Strength Index (RSI)
- GANX 57.43
- ANTX 44.51
- Support Level
- GANX $2.06
- ANTX $1.34
- Resistance Level
- GANX $2.65
- ANTX $1.28
- Average True Range (ATR)
- GANX 0.29
- ANTX 0.06
- MACD
- GANX 0.01
- ANTX -0.02
- Stochastic Oscillator
- GANX 66.36
- ANTX 21.74
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.